Telehealth company Hims & Hers crushed its end-of-2022 quarter results.
The company noted its revenue grew by more than double at the end of 2022.
The company sells a variety of health- and skin-related products directly to consumers, such as hair loss remedies, ED treatments, melatonin gummies, and more.
- The company additionally improved on its net loss, registering a net loss of $60M, better than the $108M in 2021.
- The company, which went public via a SPAC at $1.6B, noted it remains laser-focused on further trust development with its customers and delivering new and innovative products.
- Hims & Hers stock is up more than 52% YTD.
